In response to the abandonment of its program of insulin pump by patch, the Embecta company announced the removal of 125 positions. This decision, mainly impacting the Andover site in Massachusetts, reflects the company’s desire to redirect its resources towards more viable projects, while seeking to reduce its costs and clear its debts. The affected employees, mainly gathered around the development of the system, are facing a significant restructuring within the company.

Embecta, a company specializing in the development of medical devices for the treatment of diabetes, recently announced the removal of 125 positions at its Andover, Massachusetts location. This decision follows the abandonment of its program of insulin pump by patch, of which the majority of employees concerned were linked to its development. According to the information provided, these layoffs should be carried out between FEBRUARY And August 2025, with a significant impact on engineering and research and development teams. Despite approval by the FDA for an open model, the CEO clarified that a large-scale launch was not envisaged at the moment, requiring several more years of investment to reach a closed version, capable of automatically administering insulin according to the needs of the patient. patient.

Embecta and the elimination of positions

Embecta recently announced the removal of 125 positions due to the abandonment of its program of insulin pump by patch. The decision is mainly a consequence of the stratification of their product development, focused largely on the research and implementation of new solutions for the treatment of diabetes. This announcement was relayed by several media and marks a significant turning point for the company, which is now seeking to refocus its efforts on other medical devices.

The implications of this decision

According to internal sources, the majority of job cuts will concern the Andover site in Massachusetts, where the majority of work on the device took place. The affected positions are mainly related to engineering and development, reinforcing the idea that the initiative of the insulin pump was not supported by the expected results, requiring more time and investment. This restructuring will also result in savings estimated between 60 million And $65 million per year, which could give Embecta some financial flexibility to strengthen its core businesses.

A new direction for Embecta

Despite these changes, Embecta received approval from the FDA for its open-loop insulin pump. However, management has indicated that a full market launch is not planned in the short term. This still requires years of development, and the company prefers to focus on its offerings. medical devices existing. This strategy could signal a shift toward more robust and reliable solutions for patients with conditions such as type 1 diabetes Or type 2, thus minimizing the risks associated with unprofitable programs.